Product nameAnti-HNF1 alpha antibody
See all HNF1 alpha primary antibodies
DescriptionRabbit Polyclonal to HNF1 alpha
Tested applicationsSuitable for: ICC/IF, IHC-P, WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat
- Human small intestine tissue; RT-4 and U-251 MG cell lysates; Human liver tissue lysate; CACO-2 cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 40% Glycerol, 59% PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab204306 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 1 - 4 µg/ml.|
|IHC-P||1/200 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|WB||1/100 - 1/250. Predicted molecular weight: 67 kDa.|
FunctionTranscriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver. Required for the expression of several liver specific genes. Binds to the inverted palindrome 5'-GTTAATNATTAAC-3'.
Involvement in diseaseDefects in HNF1A are a cause of hepatic adenomas familial (HEPAF) [MIM:142330]. Hepatic adenomas are rare benign liver tumors of presumable epithelial origin that develop in an otherwise normal liver. Hepatic adenomas may be single or multiple. They consist of sheets of well-differentiated hepatocytes that contain fat and glycogen and can produce bile. Bile ducts or portal areas are absent. Kupffer cells, if present, are reduced in number and are non-functional. Conditions associated with adenomas are insulin-dependent diabetes mellitus and glycogen storage diseases (types 1 and 3). Note=Bi-allelic inactivation of HNF1A, whether sporadic or associated with MODY3, may be an early step in the developmant of some hepatocellular carcinomas.
Defects in HNF1A are the cause of maturity-onset diabetes of the young type 3 (MODY3) [MIM:600496]; also symbolized MODY-3. MODY is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
Defects in HNF1A are the cause of susceptibility to diabetes mellitus insulin-dependent type 20 (IDDM20) [MIM:612520]. IDDM20 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These features can result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Sequence similaritiesBelongs to the HNF1 homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
- Albumin proximal factor antibody
- Hepatic nuclear factor 1 alpha antibody
- Hepatic nuclear factor 1 antibody
All lanes : Anti-HNF1 alpha antibody (ab204306) at 1/100 dilution
Lane 1 : RT-4 cell lysate
Lane 2 : U-251 MG cell lysate
Lane 3 : Human plasma
Lane 4 : Human liver tissue lysate
Developed using the ECL technique.
Predicted band size: 67 kDa
Immunohistochemical analysis of paraffin-embedded Human small intestine tissue labeling HNF1 with ab204306 at a 1/200 dilution.
Immunofluorescent analysis of PFA-fixed, Triton X-100 permeabilized CACO-2 cells labeling HNF1 with ab204306 at 4 µg/mL (green).
This product has been referenced in:
- Yu Y et al. HNF1A/CASC2 regulates pancreatic cancer cell proliferation through PTEN/Akt signaling. J Cell Biochem 120:2816-2827 (2019). Read more (PubMed: 28865121) »
- Liang L et al. Validation of a multi-omics strategy for prioritizing personalized candidate driver genes Oncotarget 7:38440-38450 (2016). Read more (PubMed: 27469031) »